Key Takeaways:
UOB Kay Hian cut its target price for Ali Health (00241.HK) to HKD6 from HKD7.8 after the company lowered its profit growth forecast for fiscal year 2026, citing increased investment needs.
The bank maintained its "Buy" rating on the stock, according to a research report from UOB Kay Hian.
Ali Health trimmed its adjusted net profit growth target for fiscal 2026 to a range of 10-20 percent, down from a previous projection of 20-30 percent. The healthcare company attributed the revision to planned increases in investment for its innovative drug and artificial intelligence businesses.
The lowered profit outlook suggests a near-term margin contraction for Ali Health, even as it invests for future growth. Investors will watch for execution on its AI and drug initiatives to justify the increased spending.
This article is for informational purposes only and does not constitute investment advice.
